CD274 and non-small cell lung carcinoma: In the pivotal phase three trial CheckMate 227, the first-line therapy using nivolumab plus ipilimumab brought about a longer duration of overall survival (OS) than that of patients with advanced NSCLC using chemotherapy, regardless of PD-L1 expression levels (17, 18).